Is Vertex Pharmaceuticals Inc (VRTX) overvalued? · P/E 30, rev $12.00B
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
This page asks whether Vertex Pharmaceuticals Inc (VRTX) looks expensive on cached numbers — not a short thesis.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
VRTX currently screens at market cap $106.87B and trailing P/E 29.7. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VRTX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VRTX stock page for the full model, not this heading.
Not investment advice.